Benjamin W Van Tassell Selected Research

Interleukin-1 (Interleukin 1)

11/2022	Interleukin-1 blockade with anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical trials.
1/2022	Effect of IL-1 Blockade With Anakinra on Heart Failure Outcomes in Patients With Anterior Versus Nonanterior ST Elevation Myocardial Infarction.
1/2022	Effect of interleukin-1 blockade with anakinra on leukocyte count in patients with ST-segment elevation acute myocardial infarction.
1/2022	Targeting the NLRP3 inflammasome in cardiovascular diseases.
1/2020	Interleukin-1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST-Segment-Elevation Myocardial Infarction.
1/2020	Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease.
1/2019	Potential role for interleukin-1 in the cardio-renal syndrome.
1/2019	IL-1 Blockade Reduces Inflammation in Pulmonary Arterial Hypertension and Right Ventricular Failure: A Single-Arm, Open-Label, Phase IB/II Pilot Study.
8/2018	Rationale and design of the Virginia Commonwealth University-Anakinra Remodeling Trial-3 (VCU-ART3): A randomized, placebo-controlled, double-blinded, multicenter study.
1/2018	Interleukin-1 blockade for the treatment of pericarditis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Benjamin W Van Tassell Research Topics

Disease

34	Heart Failure 11/2022 - 05/2007
27	Myocardial Infarction 01/2022 - 09/2007
14	Inflammation (Inflammations) 01/2020 - 12/2011
14	Infarction (Infarctions) 01/2019 - 06/2009
9	COVID-19 01/2022 - 01/2020
9	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 09/2007
7	ST Elevation Myocardial Infarction 11/2022 - 03/2014
7	Myocardial Ischemia (Ischemic Heart Diseases) 01/2019 - 06/2009
7	Left Ventricular Dysfunction 01/2019 - 01/2012
7	Ischemia 07/2016 - 06/2009
5	Fibrosis (Cirrhosis) 01/2022 - 10/2012
4	Neoplasms (Cancer) 01/2022 - 06/2009
4	Pericarditis 01/2022 - 01/2018
4	Thrombosis (Thrombus) 01/2022 - 08/2012
4	Systolic Heart Failure 10/2020 - 01/2012
4	Hypertrophy 09/2015 - 04/2010
4	Heart Diseases (Heart Disease) 02/2015 - 10/2013
3	Dyslipidemias (Dyslipidemia) 12/2021 - 05/2021
3	Body Weight (Weight, Body) 01/2021 - 01/2018
3	Type 2 Diabetes Mellitus (MODY) 11/2020 - 06/2014
3	Reperfusion Injury 01/2019 - 10/2012
2	Infections 11/2022 - 01/2020
2	Injection Site Reaction 11/2022 - 01/2020
2	Lung Neoplasms (Lung Cancer) 01/2021 - 01/2020
2	Critical Illness (Critically Ill) 01/2021 - 01/2021
2	Myocarditis (Carditis) 01/2020 - 02/2014
2	Breast Neoplasms (Breast Cancer) 01/2020 - 01/2013
2	Cardiomyopathies (Cardiomyopathy) 01/2020 - 03/2015
2	Atherosclerosis 01/2020 - 08/2012
2	Obesity 08/2019 - 09/2007
2	Hypoxia (Hypoxemia) 01/2013 - 10/2011
2	Hypertension (High Blood Pressure) 09/2007 - 03/2007
1	Leukocytosis (Pleocytosis) 01/2022
1	Coronary Disease (Coronary Heart Disease) 01/2022
1	Stroke (Strokes) 12/2021
1	Cardiac Tamponade 12/2020
1	Constrictive Pericarditis 12/2020
1	Death (Near-Death Experience) 01/2020
1	Unstable Angina 01/2020

Drug/Important Bio-Agent (IBA)

28	Interleukin-1 (Interleukin 1)IBA 11/2022 - 02/2010
15	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 11/2022 - 05/2010
11	InflammasomesIBA 01/2022 - 12/2011
9	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 01/2022 - 01/2011
6	CytokinesIBA 08/2020 - 02/2010
5	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2022 - 05/2007
5	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 10/2021 - 09/2007
5	C-Reactive ProteinIBA 01/2020 - 11/2014
4	pro-brain natriuretic peptide (1-76)IBA 01/2022 - 01/2018
4	LipidsIBA 12/2021 - 09/2007
4	Biomarkers (Surrogate Marker)IBA 01/2020 - 08/2016
3	Colchicine FDA LinkGeneric 01/2022 - 01/2018
3	Monoclonal AntibodiesIBA 12/2021 - 07/2014
3	Proteins (Proteins, Gene)FDA Link 01/2020 - 12/2011
3	Glucose (Dextrose)FDA LinkGeneric 12/2018 - 04/2014
3	Small Interfering RNA (siRNA)IBA 01/2013 - 04/2010
2	Fibrinolytic Agents (Antithrombotic Agents)IBA 12/2021 - 01/2021
2	alirocumabIBA 12/2021 - 01/2019
2	AntibodiesIBA 12/2021 - 06/2014
2	oxidized low density lipoproteinIBA 12/2021 - 01/2019
2	Niacin (Nicotinic Acid)FDA LinkGeneric 10/2021 - 05/2021
2	HDL CholesterolIBA 10/2021 - 05/2021
2	Fibric Acids (Fibrates)IBA 10/2021 - 05/2021
2	dalcetrapibIBA 10/2021 - 05/2021
2	Triglycerides (Triacylglycerol)IBA 10/2021 - 05/2021
2	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 10/2021 - 05/2021
2	Carbon DioxideIBA 11/2020 - 01/2019
2	dapansutrileIBA 10/2020 - 01/2019
2	rilonacept FDA Link 01/2020 - 02/2010
2	canakinumab FDA Link 01/2020 - 08/2012
2	Angiotensin IIIBA 09/2015 - 10/2011
2	Doxorubicin (Adriamycin)FDA LinkGeneric 07/2015 - 01/2013
2	Troponin IIBA 07/2015 - 04/2014
2	InterleukinsIBA 03/2015 - 11/2014
2	LipopolysaccharidesIBA 02/2015 - 06/2014
2	Interleukin-18 (Interleukin 18)IBA 06/2014 - 04/2014
2	Adenosine Triphosphate (ATP)IBA 06/2014 - 12/2011
2	5- quinoxalin- 6- ylmethylenethiazolidine- 2,4- dioneIBA 12/2010 - 07/2010
1	Proprotein Convertase 9IBA 12/2021
1	evolocumabIBA 12/2021
1	Antiviral Agents (Antivirals)IBA 12/2021
1	Enoxaparin (Lovenox)FDA LinkGeneric 01/2021
1	Immunomodulating AgentsIBA 01/2021
1	sacubitril and valsartan sodium hydrate drug combinationIBA 01/2021
1	CreatinineIBA 01/2021
1	CanagliflozinIBA 11/2020
1	Sitagliptin Phosphate (Januvia)FDA Link 11/2020
1	Protein Isoforms (Isoforms)IBA 01/2020
1	Granulocyte-Macrophage Colony-Stimulating Factor Receptors (GM-CSF Receptor)IBA 01/2020
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2020
1	lenzilumabIBA 01/2020
1	mavrilimumabIBA 01/2020
1	insulin receptor-related receptor (IRR)IBA 01/2020
1	plonmarlimabIBA 01/2020

Therapy/Procedure

10	Therapeutics 01/2021 - 09/2007
4	Radiotherapy 01/2022 - 01/2020
3	Ligation 01/2019 - 06/2009
2	Extracorporeal Membrane Oxygenation 01/2022 - 01/2021
2	Critical Care (Surgical Intensive Care) 01/2022 - 08/2020
2	Drug Therapy (Chemotherapy) 12/2021 - 12/2008
1	Intranasal Administration 01/2020